Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; and Congruence Therapeutics. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
Frequently asked questions
What sector does Ono Pharmaceutical Ltd (4528) operate in?
Ono Pharmaceutical Ltd belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is Ono Pharmaceutical Ltd (4528) current stock price?
As of the latest data, Ono Pharmaceutical Ltd stock price is ¥2,389, with a previous close of ¥2,389.
What is Ono Pharmaceutical Ltd (4528) current market capitalization?
Ono Pharmaceutical Ltd market cap is approximately 1.12 trillion.
What is Ono Pharmaceutical Ltd (4528) Earnings Per Share (EPS)?
The trailing EPS is ¥148, and the forward EPS is ¥142.
What is Ono Pharmaceutical Ltd (4528) Price-to-Earnings (P/E) ratio?
Ono Pharmaceutical Ltd current P/E ratio is 16.1, with a forward P/E of 16.79.
What is Ono Pharmaceutical Ltd (4528) EBITDA?
Ono Pharmaceutical Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 40.16 billion.
Does Ono Pharmaceutical Ltd (4528) pay dividends?
Yes. Ono Pharmaceutical Ltd pays semiannual dividends with an annualized yield of 3.35% and an estimated annual payout of ¥80 per share.
When is the next ex-dividend date for Ono Pharmaceutical Ltd (4528)?
The next ex-dividend date is scheduled for September 30, 2026.
How did Ono Pharmaceutical Ltd (4528) perform in its most recent earnings report?
In the last report (June 30, 2026), Ono Pharmaceutical Ltd posted an EPS surprise of 44.14% and a revenue surprise of 3.58%.
When is Ono Pharmaceutical Ltd (4528) next earnings report?
Ono Pharmaceutical Ltd is expected to release its next earnings report on September 30, 2026.
What is Ono Pharmaceutical Ltd (4528) beta (volatility) score?
Ono Pharmaceutical Ltd has a beta of 0.132, indicating lower volatility than the overall market.
